YS Biopharma Co., Ltd. (Nasdaq: YS) is pleased to announce the results of its extraordinary general meeting (EGM) held on February 16, 2024 in Seattle, United States. The meeting was attended by shareholders who voted against the proposed resolutions. The resolutions included actions to remove several directors from office with immediate effect and to elect new directors. Despite the vote, the resolutions did not pass.
The results of the vote showed that the company had 188,327,959 ordinary shares issued and outstanding as of the record date of February 8, 2024. A total of 97,272,542 ordinary shares were voted at the EGM, with zero votes in favor and 97,272,542 votes against each resolution.
The company is also warning investors not to rely on false, unsubstantiated, and misleading statements made regarding the EGM and the company. The company has obtained an injunction order from the Grand Court of the Cayman Islands restraining certain individuals from holding themselves out to be directors of the company and taking any steps to exercise powers as directors.
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. With a focus on developing a range of preventive and therapeutic biologics, the company operates in China, the United States, Singapore, and the Philippines.
Cautionary Statement Regarding Forward-Looking Statements
YS Biopharmacautions that forward-looking statements, as contained in this press release, are based on various assumptions and are not predictions of actual performance. These statements involve risks, uncertainties, and other factors that may cause actual results to be materially different from those expressed or implied by the forward-looking statements. As such, the company encourages investors to consider the risks and uncertainties before making investment decisions based on the content of this press release.
Investor Relations Contact
For more information on YS Biopharma and its investment opportunities, please contact Robin Yang, Partner at ICR, LLC, by phone at +1 (212) 537-4035.
SOURCE YS Biopharma Co., Ltd.
Source link